Baird raised the firm’s price target on Spyre Therapeutics (SYRE) to $65 from $50 and keeps an Outperform rating on the shares. The firm said they posted better-than-expected initial data from SPY001 and thinks the data incrementally de-risks its lead asset and broad pipeline, which could offer best-in-class dosing and potentially improved efficacy in IBD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics Reports Promising Trial Results for SPY001
- Spyre Therapeutics’ SPY001 shows efficacy, safety in Phase 1 bowel disease trial
- Spyre Therapeutics Advances IBD Treatment Pipeline
- Spyre Therapeutics reports Q3 EPS ($1.36), consensus (82c)
- Spyre Therapeutics price target raised to $65 from $50 at Guggenheim